GET DAILY SIGNALSBeyondSpring (BYSI) Holds Near Flat with +1.6% Move Over 30 Days While Advancing Plinabulin
Key Takeaways
- BeyondSpring (BYSI) has traded roughly flat over the trailing 30 days, moving from about $0.79 to around $0.80 (approximately +1.6%), with notable intra-period volatility.
- The stock spiked sharply above $1.10 in late September on heavy volume before pulling back, highlighting the binary, news-driven nature of early-stage biotech trading.
- BeyondSpring's value is concentrated in Plinabulin, a first-in-class GEF-H1 agonist in late-stage development for non-small cell lung cancer (NSCLC).
- The DUBLIN-3 Phase 3 study demonstrated a statistically significant overall survival benefit, with results published in The Lancet Respiratory Medicine, supporting a planned DUBLIN-4 confirmatory trial.
- Preclinical data presented at AACR 2026 positioned Plinabulin as a potential backbone agent in antibody-drug conjugate (ADC) combination regimens.
- A July 2026 leadership transition refocused execution on advancing the DUBLIN-4 program and strengthening the company's global partner and investor base.
- For additional detail on this ticker, explore Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated strategies are positioning across the market.
Recent Trading Activity in BYSI
BeyondSpring Inc. (BYSI) is a clinical-stage biotechnology company whose shares trade in the low single-digit dollar range. Over the trailing 30 days, the stock has been essentially flat, moving from a close near $0.79 to approximately $0.80, a gain of roughly 1.6%. That headline figure, however, understates the turbulence along the way: shares surged above $1.10 in late September amid a sharp spike in trading volume before giving back much of the move over the following weeks.
This pattern is consistent with a small-cap, pre-revenue oncology developer whose share price is driven primarily by clinical data readouts, regulatory milestones, and financing news rather than fundamental earnings. With no meaningful product revenue, investor sentiment around BYSI tends to swing quickly on pipeline updates and trial progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
BeyondSpring's Pipeline Focus and Plinabulin
BeyondSpring is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, is a selective immunomodulating microtubule-binding agent (SIMBA) and GEF-H1 agonist with a multifunctional mechanism that includes dendritic cell maturation, tumor microenvironment modulation, anti-angiogenesis, and mitigation of chemotherapy-induced neutropenia.
Plinabulin is in late-stage development across multiple cancer indications and has been studied in more than 700 patients. The company's flagship opportunity is in non-small cell lung cancer (NSCLC), where Plinabulin is being advanced in combination with docetaxel. BeyondSpring also operates a targeted protein degradation (TPD) platform and retains an equity stake in SEED Therapeutics, a molecular-glue discovery company. Investors follow BYSI primarily for Plinabulin's potential to re-sensitize tumors resistant to checkpoint inhibitors and to serve as a backbone agent in combination regimens.
Key Developments Shaping the Outlook
The most significant development shaping the BeyondSpring story is the planned initiation of DUBLIN-4, a randomized, double-blind, 442-patient confirmatory Phase 3 study evaluating Plinabulin plus docetaxel in patients with non-squamous, EGFR wild-type NSCLC who have progressed on PD-1/PD-L1 inhibitor therapy. The program is designed to prospectively confirm the survival benefit observed in the DUBLIN-3 study, whose positive overall survival results were published in The Lancet Respiratory Medicine. In a mechanism-targeted non-squamous population presented in late 2025, the combination showed an overall survival hazard ratio of 0.72, a median survival improvement of 2.5 months versus docetaxel, a doubling of two- and three-year survival rates, and a reduction in grade 4 neutropenia from more than 30% to about 5%.
At the AACR Annual Meeting in April 2026, BeyondSpring presented preclinical data showing that Plinabulin enhanced both the efficacy and tolerability of topoisomerase inhibitor-based antibody-drug conjugates, with or without immune checkpoint inhibitors. The findings, which included improved complete response rates and a shift in the tumor immune environment, support Plinabulin's positioning as a potential backbone agent across ADC combination regimens. I reviewed related signals through Tickeron’s AI Trend Prediction Engine to gauge potential market reactions.
On the corporate side, the company announced a leadership transition effective July 1, 2026, appointing Min Qiu as Chief Executive Officer and Na Li as Chief Financial Officer, while co-founder Dr. Lan Huang remains Chairman. The new leadership's stated mandate is to execute the DUBLIN-4 program with discipline, extend Plinabulin's scientific optionality, and build the company's global partner and investor base.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary driver of BeyondSpring's valuation will be execution on the DUBLIN-4 confirmatory trial. Investors will monitor enrollment progress, regulatory feedback, and any interim or final overall survival data, as the study is intended to validate the DUBLIN-3 results and clarify a potential regulatory pathway.
Beyond the confirmatory trial, several factors warrant attention. Further clinical and preclinical readouts exploring Plinabulin in ADC combinations and other immuno-oncology settings could expand the asset's addressable opportunity. The company's cash position and any future financing activity remain important, given that BeyondSpring is pre-revenue and clinical trials are capital intensive. Leadership's ability to secure partnerships in China, Japan, and the United States, as well as its management of the SEED Therapeutics relationship, will also shape sentiment. Finally, broader biotech financing conditions and sector risk appetite are likely to influence trading in small-cap, data-driven names like BeyondSpring. As always with clinical-stage companies, outcomes remain uncertain, and investors should weigh the binary risks of trial results against any potential upside. From what I see, monitoring these elements closely remains essential.
Exploring Tickeron AI Tools
In my analysis of names like BYSI, I regularly consult Tickeron’s AI Trading Bots to review how different automated strategies are positioned across similar clinical-stage biotech tickers. The platform aggregates data from hundreds of bots monitoring thousands of securities, allowing users to examine varying holding periods and performance metrics without replacing personal due diligence. This approach helps provide additional context when evaluating volatile, news-driven stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BYSI turns positive, indicating new upward trend
BYSI saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 75 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BYSI just turned positive on October 30, 2026. Looking at past instances where BYSI's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.
BYSI moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +55.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BYSI advanced for three days, in 174 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for BYSI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BYSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BYSI broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BYSI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.932) is normal, around the industry mean (3.104). P/E Ratio (-4.741) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (31.056) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. BYSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BYSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the relationship between crude oil and natural gas prices?
What is the definition of the Russell 2000 Index?
Selecting AI Trading Bots: Tickeron Releases a Step-by-Step Guide
Best Audio Equipment Companies
The 2026 Semiconductor Race Report: $1.3 Trillion Already Spent on AI Chips — Here Are the 8 Stocks Still Ahead of the Curve
General Information
a manufacturer of cancer therapies
Industry Biotechnology
Advertisement